<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">34827232</PMID>
      <DateRevised>
        <Year>2021</Year>
        <Month>11</Month>
        <Day>30</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Print">2079-6382</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>10</Volume>
            <Issue>11</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Oct</Month>
              <Day>23</Day>
            </PubDate>
          </JournalIssue>
          <Title>Antibiotics (Basel, Switzerland)</Title>
          <ISOAbbreviation>Antibiotics (Basel)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Molnupiravir-A Novel Oral Anti-SARS-CoV-2 Agent.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">1294</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/antibiotics10111294</ELocationID>
        <Abstract>
          <AbstractText>Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and prevent progression to severe illness. Molnupiravir (formerly EIDD-2801), a prodrug of beta-d-N4-hydroxycytidine (EIDD-1931) and an inhibitor of RNA-dependent RNA polymerase, possesses significant activity against SARS-CoV-2. Its prophylactic efficacy has been evidenced in a ferret model. Two phase-I trials (NCT04392219 and NCT04746183) have demonstrated that oral molnupiravir is safe and well-tolerated at therapeutic doses. After five-days of oral molnupiravir therapy, satisfactory efficacies, assessed by eliminating nasopharyngeal virus in patients with early and mild COVID-19, were disclosed in two phase-II trials (NCT04405739 and NCT04405570). Two phase-II/III trials, NCT04575597 and NCT04575584, with estimated enrollments of 1850 and 304 cases, respectively, are ongoing. The NCT04575597 recently released that molnupiravir significantly reduced the risk of hospitalization or death in adults experiencing mild or moderate COVID-19. To benefit individual and public health, clinical applications of molnupiravir to promptly treat COVID-19 patients and prevent SARS-CoV-2 transmission may be expected.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Lee</LastName>
            <ForeName>Ching-Chi</ForeName>
            <Initials>CC</Initials>
            <Identifier Source="ORCID">0000-0002-4949-2742</Identifier>
            <AffiliationInfo>
              <Affiliation>Clinical Medicine Research Center, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hsieh</LastName>
            <ForeName>Chih-Chia</ForeName>
            <Initials>CC</Initials>
            <Identifier Source="ORCID">0000-0002-7465-5742</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Emergency Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ko</LastName>
            <ForeName>Wen-Chien</ForeName>
            <Initials>WC</Initials>
            <Identifier Source="ORCID">0000-0001-7497-149X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan 704, Taiwan.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Department of Medicine, College of Medicine, National Cheng Kung University, Tainan 701, Taiwan.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Antibiotics (Basel)</MedlineTA>
        <NlmUniqueID>101637404</NlmUniqueID>
        <ISSNLinking>2079-6382</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">COVID-19</Keyword>
        <Keyword MajorTopicYN="Y">RNA polymerase inhibitor</Keyword>
        <Keyword MajorTopicYN="Y">antiviral agents</Keyword>
        <Keyword MajorTopicYN="Y">clinical trial</Keyword>
        <Keyword MajorTopicYN="Y">molnupiravir</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>3</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>20</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>27</Day>
          <Hour>1</Hour>
          <Minute>2</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>11</Month>
          <Day>28</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34827232</ArticleId>
        <ArticleId IdType="pmc">PMC8614993</ArticleId>
        <ArticleId IdType="doi">10.3390/antibiotics10111294</ArticleId>
        <ArticleId IdType="pii">antibiotics10111294</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Zhang L., Shen F.-M., Chen F., Lin Z. Origin and evolution of the 2019 novel coronavirus. Clin. Infect. Dis. 2020;71:882–883. doi: 10.1093/cid/ciaa112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/cid/ciaa112</ArticleId>
            <ArticleId IdType="pmc">PMC7108176</ArticleId>
            <ArticleId IdType="pubmed">32011673</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chan J.F.-W., To K.K.-W., Tse H., Jin D.-Y., Yuen K.-Y. Interspecies transmission and emergence of novel viruses: Lessons from bats and birds. Trends Microbiol. 2013;21:544–555. doi: 10.1016/j.tim.2013.05.005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.tim.2013.05.005</ArticleId>
            <ArticleId IdType="pmc">PMC7126491</ArticleId>
            <ArticleId IdType="pubmed">23770275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Memish Z.A., Zumla A.I., Al-Hakeem R.F., Al-Rabeeah A.A., Stephens G.M. Family cluster of Middle East respiratory syndrome coronavirus infections. N. Engl. J. Med. 2013;368:2487–2494. doi: 10.1056/NEJMoa1303729.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1303729</ArticleId>
            <ArticleId IdType="pubmed">23718156</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhong N., Zheng B., Li Y., Poon L., Xie Z., Chan K., Li P., Tan S., Chang Q., Xie J. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003;362:1353–1358. doi: 10.1016/S0140-6736(03)14630-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(03)14630-2</ArticleId>
            <ArticleId IdType="pmc">PMC7112415</ArticleId>
            <ArticleId IdType="pubmed">14585636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y., Qiu Y., Wang J., Liu Y., Wei Y. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395:507–513. doi: 10.1016/S0140-6736(20)30211-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30211-7</ArticleId>
            <ArticleId IdType="pmc">PMC7135076</ArticleId>
            <ArticleId IdType="pubmed">32007143</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>WHO  Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update.  [(accessed on 16 June 2021)].  Available online:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</Citation>
        </Reference>
        <Reference>
          <Citation>Vetter P., Vu D.L., L’Huillier A.G., Schibler M., Kaiser L., Jacquerioz F. Clinical features of Covid-19. BMJ. 2020;369:1470. doi: 10.1136/bmj.m1470.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.m1470</ArticleId>
            <ArticleId IdType="pubmed">32303495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai C.-C., Shih T.-P., Ko W.-C., Tang H.-J., Hsueh P.-R. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int. J. Antimicrob. Agents. 2020;55:105924. doi: 10.1016/j.ijantimicag.2020.105924.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ijantimicag.2020.105924</ArticleId>
            <ArticleId IdType="pmc">PMC7127800</ArticleId>
            <ArticleId IdType="pubmed">32081636</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323:1061–1069. doi: 10.1001/jama.2020.1585.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId>
            <ArticleId IdType="pmc">PMC7042881</ArticleId>
            <ArticleId IdType="pubmed">32031570</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X. Clinical features of patients infected with 2019 novel Coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId>
            <ArticleId IdType="pmc">PMC7159299</ArticleId>
            <ArticleId IdType="pubmed">31986264</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kandeel M., Yamamoto M., Tani H., Kobayashi A., Gohda J., Kawaguchi Y., Park B.K., Kwon H.-J., Inoue J.-I., Alkattan A. Discovery of new fusion inhibitor peptides against SARS-CoV-2 by targeting the spike S2 subunit. Biomol. Ther. 2021;29:282. doi: 10.4062/biomolther.2020.201.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4062/biomolther.2020.201</ArticleId>
            <ArticleId IdType="pmc">PMC8094075</ArticleId>
            <ArticleId IdType="pubmed">33424013</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vicenti I., Zazzi M., Saladini F. SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19. Expert Opin. Ther. Pat. 2021;31:325–337. doi: 10.1080/13543776.2021.1880568.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/13543776.2021.1880568</ArticleId>
            <ArticleId IdType="pmc">PMC7938656</ArticleId>
            <ArticleId IdType="pubmed">33475441</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Caruso A., Caccuri F., Bugatti A., Zani A., Vanoni M., Bonfanti P., Cazzaniga M.E., Perno C.F., Messa C., Alberghina L. Methotrexate inhibits SARS-CoV-2 virus replication “in vitro”. J. Med. Virol. 2021;93:1780–1785. doi: 10.1002/jmv.26512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/jmv.26512</ArticleId>
            <ArticleId IdType="pmc">PMC7891346</ArticleId>
            <ArticleId IdType="pubmed">32926453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Amin S.A., Jha T. Fight against novel coronavirus: A perspective of medicinal chemists. Eur. J. Med. Chem. 2020;201:112559. doi: 10.1016/j.ejmech.2020.112559.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ejmech.2020.112559</ArticleId>
            <ArticleId IdType="pmc">PMC7289749</ArticleId>
            <ArticleId IdType="pubmed">32563814</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lai C.-C., Chen C.-H., Wang C.-Y., Chen K.-H., Wang Y.-H., Hsueh P.-R. Clinical efficacy and safety of remdesivir in patients with COVID-19: A systematic review and network meta-analysis of randomized controlled trials. J. Antimicrob. Chemother. 2021;76:1962–1968. doi: 10.1093/jac/dkab093.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/jac/dkab093</ArticleId>
            <ArticleId IdType="pmc">PMC8083728</ArticleId>
            <ArticleId IdType="pubmed">33758946</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reynard O., Nguyen X.-N., Alazard-Dany N., Barateau V., Cimarelli A., Volchkov V.E. Identification of a new ribonucleoside inhibitor of ebola virus replication. Viruses. 2015;7:6233–6240. doi: 10.3390/v7122934.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/v7122934</ArticleId>
            <ArticleId IdType="pmc">PMC4690858</ArticleId>
            <ArticleId IdType="pubmed">26633464</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.-J., Hart M., Natchus M.G., Painter G.R., Plemper R.K. Quantitative efficacy paradigms of the influenza clinical drug candidate EIDD-2801 in the ferret model. Transl. Res. 2020;218:16–28. doi: 10.1016/j.trsl.2019.12.002.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.trsl.2019.12.002</ArticleId>
            <ArticleId IdType="pmc">PMC7568909</ArticleId>
            <ArticleId IdType="pubmed">31945316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Urakova N., Kuznetsova V., Crossman D.K., Sokratian A., Guthrie D.B., Kolykhalov A.A., Lockwood M.A., Natchus M.G., Crowley M.R., Painter G.R. β-d-N4-hydroxycytidine is a potent anti-alphavirus compound that induces a high level of mutations in the viral genome. J. Virol. 2018;92:e01965-17. doi: 10.1128/JVI.01965-17.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01965-17</ArticleId>
            <ArticleId IdType="pmc">PMC5774879</ArticleId>
            <ArticleId IdType="pubmed">29167335</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Agostini M.L., Pruijssers A.J., Chappell J.D., Gribble J., Lu X., Andres E.L., Bluemling G.R., Lockwood M.A., Sheahan T.P., Sims A.C. Small-molecule antiviral β-d-N4-hydroxycytidine inhibits a proofreading-intact coronavirus with a high genetic barrier to resistance. J. Virol. 2019;93:e01348-19. doi: 10.1128/JVI.01348-19.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/JVI.01348-19</ArticleId>
            <ArticleId IdType="pmc">PMC6880162</ArticleId>
            <ArticleId IdType="pubmed">31578288</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hernandez-Santiago B.I., Beltran T., Stuyver L., Chu C.K., Schinazi R.F. Metabolism of the anti-hepatitis C virus nucleoside β-d-N4-hydroxycytidine in different liver cells. Antimicrob. Agents Chemother. 2004;48:4636–4642. doi: 10.1128/AAC.48.12.4636-4642.2004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.48.12.4636-4642.2004</ArticleId>
            <ArticleId IdType="pmc">PMC529212</ArticleId>
            <ArticleId IdType="pubmed">15561837</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter G.R., Bowen R.A., Bluemling G.R., DeBergh J., Edpuganti V., Gruddanti P.R., Guthrie D.B., Hager M., Kuiper D.L., Lockwood M.A. The prophylactic and therapeutic activity of a broadly active ribonucleoside analog in a murine model of intranasal venezuelan equine encephalitis virus infection. Antivir. Res. 2019;171:104597. doi: 10.1016/j.antiviral.2019.104597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.antiviral.2019.104597</ArticleId>
            <ArticleId IdType="pubmed">31494195</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gao Y., Yan L., Huang Y., Liu F., Zhao Y., Cao L., Wang T., Sun Q., Ming Z., Zhang L. Structure of the RNA-dependent RNA polymerase from COVID-19 virus. Science. 2020;368:779–782. doi: 10.1126/science.abb7498.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abb7498</ArticleId>
            <ArticleId IdType="pmc">PMC7164392</ArticleId>
            <ArticleId IdType="pubmed">32277040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Toots M., Yoon J.-J., Cox R.M., Hart M., Sticher Z.M., Makhsous N., Plesker R., Barrena A.H., Reddy P.G., Mitchell D.G. Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia. Sci. Transl. Med. 2019;11:eaax5866. doi: 10.1126/scitranslmed.aax5866.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.aax5866</ArticleId>
            <ArticleId IdType="pmc">PMC6848974</ArticleId>
            <ArticleId IdType="pubmed">31645453</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sheahan T.P., Sims A.C., Zhou S., Graham R.L., Pruijssers A.J., Agostini M.L., Leist S.R., Schäfer A., Dinnon K.H., Stevens L.J. An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice. Sci. Transl. Med. 2020;12:eabb5883. doi: 10.1126/scitranslmed.abb5883.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/scitranslmed.abb5883</ArticleId>
            <ArticleId IdType="pmc">PMC7164393</ArticleId>
            <ArticleId IdType="pubmed">32253226</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wahl A., Gralinski L.E., Johnson C.E., Yao W., Kovarova M., Dinnon K.H., Liu H., Madden V.J., Krzystek H.M., De C. SARS-CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature. 2021;591:451–457. doi: 10.1038/s41586-021-03312-w.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41586-021-03312-w</ArticleId>
            <ArticleId IdType="pmc">PMC7979515</ArticleId>
            <ArticleId IdType="pubmed">33561864</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cox R.M., Wolf J.D., Plemper R.K. Therapeutically administered ribonucleoside analogue MK-4482/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets. Nat. Microbiol. 2021;6:11–18. doi: 10.1038/s41564-020-00835-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41564-020-00835-2</ArticleId>
            <ArticleId IdType="pmc">PMC7755744</ArticleId>
            <ArticleId IdType="pubmed">33273742</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Abdelnabi R., Foo C.S., De Jonghe S., Maes P., Weynand B., Neyts J. Molnupiravir inhibits the replication of the emerging SARS-CoV-2 variants of concern (VoCs) in a hamster infection model. J. Infect. Dis. 2021;224:749–753. doi: 10.1093/infdis/jiab361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/infdis/jiab361</ArticleId>
            <ArticleId IdType="pmc">PMC8408768</ArticleId>
            <ArticleId IdType="pubmed">34244768</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gordon C.J., Tchesnokov E.P., Schinazi R.F., Götte M. Molnupiravir promotes SARS-CoV-2 mutagenesis via the RNA template. J. Biol. Chem. 2021:100770. doi: 10.1016/j.jbc.2021.100770.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jbc.2021.100770</ArticleId>
            <ArticleId IdType="pmc">PMC8110631</ArticleId>
            <ArticleId IdType="pubmed">33989635</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter W.P., Holman W., Bush J.A., Almazedi F., Malik H., Eraut N.C., Morin M.J., Szewczyk L.J., Painter G.R. Human safety, tolerability, and pharmacokinetics of molnupiravir, a novel broad-spectrum oral antiviral agent with activity against SARS-CoV-2. Antimicrob. Agents Chemother. 2021;65:e02428-20. doi: 10.1128/AAC.02428-20.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1128/AAC.02428-20</ArticleId>
            <ArticleId IdType="pmc">PMC8092915</ArticleId>
            <ArticleId IdType="pubmed">33649113</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Khoo S.H., FitzGerald R., Fletcher T., Ewings S., Jaki T., Lyon R., Downs N., Walker L., Tansley-Hancock O., Greenhalf W. Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: A phase 1, dose-escalating, randomised controlled study. medRxiv. 2021</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC8598307</ArticleId>
            <ArticleId IdType="pubmed">34450619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Painter W., Sheahan T., Baric R., Holman W., Donovan J., Fang L., Alabanza P., Eron J., Goecker E., Coombs R. Reduction in infectious SARS-COV-2 in treatment study of covid-19 with molnupiravir. Top. Antivir. Med. 2021:304–305.</Citation>
        </Reference>
        <Reference>
          <Citation>Fischer W.A., Eron J.J., Holman W., Cohen M.S., Fang L., Szewczyk L.J., Sheahan T.P., Baric R.S., Mollan K.R., Wolfe C.R. Molnupiravir, an Oral Antiviral Treatment for COVID-19. medRxiv. 2021 doi: 10.1101/2021.06.17.21258639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/2021.06.17.21258639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffiths G., Fitzgerald R., Jaki T., Corkhill A., Marwood E., Reynolds H., Stanton L., Ewings S., Condie S., Wrixon E. AGILE-ACCORD: A randomized, multicentre, seamless, adaptive phase I/II platform study to determine the optimal dose, safety and efficacy of multiple candidate agents for the treatment of COVID-19: A structured summary of a study protocol for a randomised platform trial. Trials. 2020;21:1–3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC7303573</ArticleId>
            <ArticleId IdType="pubmed">32560744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Clinicaltrials.gov.  [(accessed on 3 October 2021)]; Available online:  https://clinicaltrials.gov/ct2/home.</Citation>
        </Reference>
        <Reference>
          <Citation>Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study.  [(accessed on 3 October 2021)].  Available online:  https://www.merck.com/news/merck-and-ridgebacks-investigational-oral-antiviral-molnupiravir-reduced-the-risk-of-hospitalization-or-death-by-approximately-50-percent-compared-to-placebo-for-patients-with-mild-or-moderat/</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
